Sterile affinity chromatography resin

US10071364B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10071364-B2
Application numberUS-201514598401-A
CountryUS
Kind codeB2
Filing dateJan 16, 2015
Priority dateJan 17, 2014
Publication dateSep 11, 2018
Grant dateSep 11, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are methods of reducing bioburden of (e.g., sterilizing) a chromatography resin that include exposing a container including a composition including a chromatography resin and at least one antioxidant agent and/or chelator to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one antioxidant agent and/or chelator are present in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after/upon exposure to the dose of gamma-irradiation. Also provided are reduced bioburden chromatography columns including the reduced bioburden chromatography resin, compositions including a chromatography resin and at least one chelator and/or antioxidant agent, methods of performing reduced bioburden column chromatography using one of these reduced bioburden chromatography columns, and integrated, closed, and continuous processes for reduced bioburden manufacturing of a purified recombinant protein.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of reducing bioburden of an affinity chromatography resin comprising: exposing a container comprising a composition comprising (i) an affinity chromatography resin and (ii) a liquid comprising at least one chelator to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the affinity chromatography resin, wherein the at least one chelator is present in an amount sufficient to ameliorate the loss of binding capacity of the affinity chromatography resin after exposure to the dose of gamma-irradiation. 2. The method of claim 1 , wherein the container is a storage vessel. 3. The method of claim 1 , wherein the container is a packed chromatography column. 4. The method of claim 1 , wherein the composition comprises at least one chelator selected from the group consisting of: ethylenediaminetetraacetic acid (EDTA), 2,3-dimercapto-1-propanesulfonic acid sodium (DMPS), dimercaptosuccinic acid (DMSA), metallothionin, and desferroxamine. 5. The method of claim 1 , wherein the dose is between about 15 kGy to about 45 kGy. 6. A composition comprising (i) an affinity chromatography resin and (ii) a liquid comprising at least one chelator, wherein the at least one chelator is present in an amount sufficient to ameliorate the loss of binding capacity of the affinity chromatography resin upon treatment with a dose of gamma-irradiation sufficient to reduce bioburden of the composition. 7. The method of claim 1 , wherein the container is a chromatography column. 8. The method of claim 1 , wherein the composition is a slurry of sedimented affinity chromatography resin in the liquid. 9. The method of claim 8 , wherein the liquid is a buffered solution. 10. A method of reducing bioburden of an affinity chromatography resin comprising: exposing a container comprising a composition comprising an affinity chromatography resin and at least one antioxidant agent to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the affinity chromatography resin, wherein the at least one antioxidant agent is present in an amount sufficient to ameliorate the loss of binding capacity of the affinity chromatography resin after exposure to the dose of gamma-irradiation. 11. The method of claim 10 , wherein the container is a storage vessel. 12. The method of claim 10 , wherein the container is a chromatography column. 13. The method of claim 10 , wherein the container is a packed chromatography column. 14. The method of claim 10 , wherein the composition further comprises at least one chelator. 15. The method of claim 10 , wherein the composition is a slurry of sedimented affinity chromatography resin in the liquid. 16. The method of claim 15 , wherein the liquid is a buffered solution. 17. The method of claim 10 , wherein the composition is a solid mixture. 18. The method of claim 10 , wherein the composition comprises at least one antioxidant agent selected from the group consisting of: reduced glutathione, reduced thioredoxin, reduced cysteine, a carotenoid, melatonin, lycopene, tocopherol, reduced ubiquinone, ascorbate, bilirubin, uric acid, lipoic acid, a flavonoid, a phenolpropanoid acid, lidocaine, naringenin, fullerene, glucose, mannitol, 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl, and dimethylmethoxy chromanol. 19. The method of claim 10 , wherein the dose is between about 15 kGy and about 45 kGy. 20. A method of reducing bioburden of an affinity chromatography resin comprising: exposing a container comprising a composition comprising an affinity chromatography resin and methionine and/or histidine to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the affinity chromatography resin, wherein the methionine and/or histidine is present in an amount sufficient to ameliorate the loss of binding capacity of the affinity chromatography resin after exposure to the dose of gamma-irradiation. 21. The method of claim 20 , wherein the composition comprises an affinity chromatography resin and between about 5 mM and about 150 mM methionine. 22. The method of claim 20 , wherein the composition comprises an affinity chromatography resin and between about 5 mM and about 150 mM histidine. 23. The method of claim 20 , wherein the composition comprises an affinity chromatography resin, between about 5 mM and about 150 mM methionine, and about 5 mM and about 150 mM histidine. 24. The method of claim 20 , wherein the container is a storage vessel. 25. The method of claim 20 , wherein the container is a chromatography column. 26. The method of claim 20 , wherein the container is a packed chromatography column. 27. The method of claim 20 , wherein the composition is a solid mixture. 28. The method of claim 20 , wherein the composition is a sedimented slurry of affinity chromatography resin in a liquid comprising the methionine and/or histidine. 29. The method of claim 28 , wherein the liquid is a buffered solution. 30. The method of claim 20 , wherein the dose is between about 15 kGy and about 45 kGy. 31. A composition comprising an affinity chromatography resin and at least one antioxidant agent, wherein the at least one antioxidant agent is present in an amount sufficient to ameliorate the loss of binding capacity of the affinity chromatography resin upon treatment with a dose of gamma-irradiation sufficient to reduce bioburden of the composition, wherein the at least one antioxidant agent is selected from the group consisting of: reduced glutathione, reduced thioredoxin, reduced cysteine, a carotenoid, melatonin, lycopene, tocopherol, reduced ubiquinone, ascorbate, bilirubin, uric acid, lipoic acid, a flavonoid, a phenolpropanoid acid, lidocaine, naringenin, fullerene, glucose, mannitol, 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl, and dimethylmethoxy chromanol. 32. The composition of claim 31 , wherein the at least one antioxidant agent is selected from the group consisting of: mannitol, sodium ascorbate, methionine, and histidine. 33. The composition of claim 32 , wherein the at least one antioxidant agent is one or both of methionine and histidine.

Assignees

Inventors

Classifications

  • Ion-exchange chromatography · CPC title

  • Sorbents specially adapted for preparative, analytical or investigative chromatography · CPC title

  • Assembling or joining · CPC title

  • relating to the conditioning of the sorbent material · CPC title

  • Anion exchangers for chromatographic processes · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10071364B2 cover?
Provided herein are methods of reducing bioburden of (e.g., sterilizing) a chromatography resin that include exposing a container including a composition including a chromatography resin and at least one antioxidant agent and/or chelator to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one antioxidant agent and/o…
Who is the assignee on this patent?
Genzyme Corp
What technology area does this patent fall under?
Primary CPC classification B01J20/3441. Mapped technology areas include Operations & Transport.
When was this patent published?
Publication date Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).